71 related articles for article (PubMed ID: 37304292)
1. Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area.
Stroh GR; Peikert T; Escalante P
Cancer Immunol Immunother; 2021 Nov; 70(11):3105-3111. PubMed ID: 33770211
[TBL] [Abstract][Full Text] [Related]
2. Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study.
Fujita K; Elkington P; Redelman-Sidi G; Kanai O; Yamamoto Y; Imakita T; Okamura M; Nakatani K; Mio T
Cancer Immunol Immunother; 2022 Nov; 71(11):2757-2764. PubMed ID: 35429244
[TBL] [Abstract][Full Text] [Related]
3. Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients.
Xu Y; Zhang Q; Chen Z; Yang S; Chen H; Xiao X; Jiang H
BMC Pulm Med; 2024 Apr; 24(1):174. PubMed ID: 38609918
[TBL] [Abstract][Full Text] [Related]
4. A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment.
Hirano S; Takahashi H; Nakamura S; Matsuda K; Ishikawa R; Tamura K; Shikano K; Fujita T; Amano H; Nakamura M
Chin Clin Oncol; 2024 May; ():. PubMed ID: 38859608
[TBL] [Abstract][Full Text] [Related]
5. Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature.
Tay SH; Toh MMX; Thian YL; Vellayappan BA; Fairhurst AM; Chan YH; Aminkeng F; Bharwani LD; Huang Y; Mak A; Wong ASC
Front Immunol; 2022; 13():807050. PubMed ID: 35154124
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy with immune checkpoint inhibitors and infections: A particular focus on mycobacterial infections.
Fujita K; Elkington PT
Respir Investig; 2024 May; 62(3):339-347. PubMed ID: 38417355
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review.
Kitchlu A; Jhaveri KD; Sprangers B; Yanagita M; Wanchoo R
Clin Kidney J; 2021 Sep; 14(9):2012-2022. PubMed ID: 34476087
[TBL] [Abstract][Full Text] [Related]
8. Late Tuberculosis Reactivation After Severe Covid-19.
Dormans T; Zandijk E; Stals F
Eur J Case Rep Intern Med; 2024; 11(5):004406. PubMed ID: 38715882
[TBL] [Abstract][Full Text] [Related]
9. Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis.
Otoshi R; Ikeda S; Kaneko T; Sagawa S; Yamada C; Kumagai K; Moriuchi A; Sekine A; Baba T; Ogura T
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730686
[TBL] [Abstract][Full Text] [Related]
10. Cytokine release syndrome induced by immune checkpoint inhibitor treatment for uterine cervical cancer recurrence: A case report.
Sekimata M; Kinjo Y; Tohyama A; Murakami M; Hashiwaki S; Saito Y; Higami S; Hagimoto M; Taketomi R; Hoshino K; Harada H; Ueda T; Kurita T; Matsuura Y; Yoshino K
Oncol Lett; 2024 Jul; 28(1):331. PubMed ID: 38807673
[TBL] [Abstract][Full Text] [Related]
11. Deciphering the Correlation between the Emergence of Lung Carcinoma Associated with Tuberculosis-related Inflammation.
Chauhan P; Pandey P; Ramniwas S; Khan F; Maqsood R
Endocr Metab Immune Disord Drug Targets; 2024 May; ():. PubMed ID: 38831573
[TBL] [Abstract][Full Text] [Related]
12. Progress in mechanism-based diagnosis and treatment of tuberculosis comorbid with tumor.
Wang C; Zou RQ; He GZ
Front Immunol; 2024; 15():1344821. PubMed ID: 38298194
[TBL] [Abstract][Full Text] [Related]
13. A case of congenital tuberculosis with a favorable outcome in a full term neonate.
Varimo T; Nieminen T; Aronniemi J; Kekomäki S; Teivaanmäki T; Metsäranta M
Clin Case Rep; 2020 Sep; 8(9):1802-1805. PubMed ID: 32983499
[TBL] [Abstract][Full Text] [Related]
14. Fever of unknown origin associated with immune checkpoint inhibitors.
Tong X; Zhan T; Dong X; Xu D
Front Immunol; 2024; 15():1364128. PubMed ID: 38533499
[TBL] [Abstract][Full Text] [Related]
15. A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?
Vaddi A; Hulsebus HJ; O'Neill EL; Knight V; Chan ED
J Thorac Dis; 2024 Feb; 16(2):1601-1624. PubMed ID: 38505086
[TBL] [Abstract][Full Text] [Related]
16. Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review.
Lin C; Xu G; Gao S; Feng T; Li S
Front Immunol; 2023; 14():1162190. PubMed ID: 37304292
[TBL] [Abstract][Full Text] [Related]
17. Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.
Chen HW; Kuo YW; Chen CY; Chang CH; Wang SM; Chien YC; Lu WC; Chen JP; Chang CY; Wei YF; Chang SC; Shu CC; Wang JY; Liao WY; Wang HC; Yu CJ
Oncologist; 2024 Apr; 29(4):e498-e506. PubMed ID: 38227604
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
